Abstract
Background: Alzheimer's disease (AD) is a neurodegenerative disease characterised by a progressive decline in cognitive function and represents a major healthcare challenge worldwide. Increasing evidence indicates that mitochondrial dysfunction mediated oxidative stress plays a significant role in the pathophysiological process of AD. Therefore, the physiological activation of antioxidant enzymes that respond to increased oxidative stress is thought to prevent neuropathology. One of those endogenous defences is NADPH quinone oxidoreductase 1 (NQO1). NQO1 is a cytosolic homodimeric flavoprotein that catalyses the two-electron reduction of quinones and related molecules aimed at increasing their solubility and excretion. In line with its role as a phase II stress response protein, altered NQO1 expression is associated with several pathological conditions and disorders including AD.
Conclusion: This review summarizes the association between NQO1 and AD pathology. Understanding this association will provide further insight into the pathogenesis of the disease. More importantly, recent interest in drugs that affect NQO1 expression or its activity provides hope that this approach could lead to novel therapeutic options for the treatment of AD.
Keywords: Alzheimer's disease (AD), NADPH Quinone Oxidoreductase 1 (NQO1), neurofibrillary tangles (NFT), amyloid-β, mitochondrial dysfunction, neurodegenerative disease.
Current Alzheimer Research
Title:Alzheimer's Disease and NQO1: Is there a Link?
Volume: 15 Issue: 1
Author(s): Jamuna Chhetri*, Anna E. King and Nuri Gueven
Affiliation:
- Division of Pharmacy, School of Medicine, Faculty of Health, University of Tasmania, Hobart, TAS 7001,Australia
Keywords: Alzheimer's disease (AD), NADPH Quinone Oxidoreductase 1 (NQO1), neurofibrillary tangles (NFT), amyloid-β, mitochondrial dysfunction, neurodegenerative disease.
Abstract: Background: Alzheimer's disease (AD) is a neurodegenerative disease characterised by a progressive decline in cognitive function and represents a major healthcare challenge worldwide. Increasing evidence indicates that mitochondrial dysfunction mediated oxidative stress plays a significant role in the pathophysiological process of AD. Therefore, the physiological activation of antioxidant enzymes that respond to increased oxidative stress is thought to prevent neuropathology. One of those endogenous defences is NADPH quinone oxidoreductase 1 (NQO1). NQO1 is a cytosolic homodimeric flavoprotein that catalyses the two-electron reduction of quinones and related molecules aimed at increasing their solubility and excretion. In line with its role as a phase II stress response protein, altered NQO1 expression is associated with several pathological conditions and disorders including AD.
Conclusion: This review summarizes the association between NQO1 and AD pathology. Understanding this association will provide further insight into the pathogenesis of the disease. More importantly, recent interest in drugs that affect NQO1 expression or its activity provides hope that this approach could lead to novel therapeutic options for the treatment of AD.
Export Options
About this article
Cite this article as:
Chhetri Jamuna*, King E. Anna and Gueven Nuri, Alzheimer's Disease and NQO1: Is there a Link?, Current Alzheimer Research 2018; 15 (1) . https://dx.doi.org/10.2174/1567205014666170203095802
DOI https://dx.doi.org/10.2174/1567205014666170203095802 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Yeast-Derived β-Glucan in Combination with Anti-Tumor Monoclonal Antibody Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimers Disease
Current Alzheimer Research Molecular Targets of Tannic Acid in Alzheimer's Disease
Current Alzheimer Research 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges
Current Drug Targets Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Apolipoprotein E-mediated Modulation of ADAM10 in Alzheimer's Disease
Current Alzheimer Research Computational Models for 5αR Inhibitors for Treatment of Prostate Cancer: Review of Previous Works and Screening of Natural Inhibitors of 5αR2
Current Computer-Aided Drug Design Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Combating Protein Misfolding and Aggregation by Intracellular Antibodies
Current Molecular Medicine Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics Proteases as Anti-Cancer Targets - Molecular and Biological Basis for Development of Inhibitor-Like Drugs Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Updates of mTOR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry The Novel Multi-Target Iron Chelator, M30 Modulates HIF-1α-Related Glycolytic Genes and Insulin Signaling Pathway in the Frontal Cortex of APP/PS1 Alzheimer’s Disease Mice
Current Alzheimer Research Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials Regulation of Autophagy in Oxygen-Dependent Cellular Stress
Current Pharmaceutical Design The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis
Current Drug Targets